Ms. Qing Huang has over 20 years of global practical experience in CMC, manufacturing management, capacity expansion, lean operations, and business development in the domestic and international biopharmaceutical industry. She previously served as Senior Scientist, Senior Manager, and Site Manager in BMS and Abbott/AbbVie in the US, responsible for developing several processing platforms and leading a team to achieve lean operations. Responsible for the technical start up of a large-scale commercial manufacturing facility in Singapore assigned by Abbott, she successfully led intercontinental technology transfer and production scale-up, and passed multi-national GMP inspections for Humira®, an innovative biopharmaceutical product with annual global sales of more than 20 billions USD in 2021. After coming back to China, she served as General Manager in Chengdu Kanghong Biotech, in charge of the commercial manufacture of Lumitin®, an innovative bio-therapeutic medicine, and multiple S&T progress projects.
Mr. Shuhei Shimizu has over 20 years of business development, marketing, and senior management experience in the international pharmaceutical industry. He served as Vice President of business development and other senior/executive leadership positions with Eisai’s USA operations, in charge of global commercialization and partnerships in the disease/business area, including but not limited to business development, alliance management, global marketing, global value & access, sales and marketing, and clinical project management in oncology. He led and participated in the strategic acquisition of several US companies by Eisai.
“It is a great honor to invite Huang Qing and Shuhei Shimizu to join BlissBio,” said Dr. Ziping Wei, Chairman, Co-founder and CEO of BlissBio. “Ms. Huang has very rich experience in the development and manufacturing of biopharmaceuticals. We believe that the arrival of Mr. Shimizu will further improve the business collaborations with international pharmaceutical companies. Their participation in BlissBio will accelerate the development and commercialization of multiple innovative drugs, and provide patients with safer and more effective drugs as soon as possible."
About BlissBio
Bliss Biopharmaceutical (Hangzhou) Co., Ltd., founded in Qiantang Area, Hangzhou, Zhejiang Province in December 2017 by a number of US returnees, is a clinical-stage biopharmaceutical company focusing on discovery, development, and commercialization of biotherapeutics with independent intellectual properties. The clinical studies of two innovative ADC products, BB-1701 and BB-1705, are being conducted in China and U.S, both targeting broad market prospects for multiple oncology indications. BlissBio's core team has successful experience in product development and commercialization, a variety of technological platforms, as well as manufacturing capability of antibodies and ADCs that meet international GMP standards. With “Together, let’s improve human health” as the core value, BlissBio has close collaborations with domestic and foreign biopharmaceutical companies to develop internationally competitive BIC and FIC biotherapeutics.
